Neuroelectrics has unveiled promising findings from a telemedicine pilot study exploring the efficacy of at-home transcranial direct current stimulation (tDCS) using its Starstim device for managing major depressive disorder (MDD). The study involved 35 participants with medication-resistant MDD who underwent 37 sessions of at-home tDCS targeting the left dorsolateral prefrontal cortex over an eight-week period. The results revealed a substantial 64% median reduction in observer-rated MADRS scores, indicating significant and clinically meaningful improvement in depressive symptoms. Moreover, over 70% of participants showcased a remarkable ≥50% improvement, and the response rate reached 73%, emphasising the potential of remotely-supervised tDCS therapy with Starstim as a safe and effective option for MDD patients.
Notably, the study demonstrated the safety and feasibility of at-home tDCS, with almost 90% of participants completing the treatment without encountering adverse effects. The primary efficacy measure, the median percent change in the Montgomery-Asberg Depression Mood Rating (MADRS) from baseline to the end of the 4-week follow-up period, underscored the positive impact of the therapy. Secondary measures, including the Quick Inventory of Depressive Symptomatology-Self Report (QUIDS-SR) and the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF), also showed significant enhancements, supporting the effectiveness of tDCS in reducing depressive symptoms.
The CEO of Neuroelectrics, Ana Maiques, expressed excitement about the transformative potential of at-home tDCS therapy with the Starstim device, marking a significant advancement in improving accessibility and treatment outcomes for individuals struggling with MDD. The results were hailed as a promising option for those who have not found relief through traditional pharmacologic therapies, opening up new possibilities for managing depression through innovative, remotely-supervised approaches.
Click here to read the original news story.